Background and aims: Worldwide Interferon-free regimens with direct acting antiviral agents (DAAs) are the standard treatment for chronic hepatitis today. Different studies have shown that DAAs have favorable safety profile and high rates of sustained virological response (SVR) compared with IFN-based treatments. Therefore, this study aims to assess the rate SVR in patients treated with sofosbuvir-based regimens in Sohag Governate and to evaluate the adverse events (AEs) and the biochemical response to therapy in the studied patients.

Patients and Methods: Our study was a prospective one conducted on 135 patients eligible for treatment with sofosbuvir-based regimens. Patients were categorized into two groups: Group 1 (easy to treat) which was treated with dual therapy (sofosbuvir plus daclatasvir) and group 2 (difficult to treat) which was treated with triple therapy (sofosbuvir plus daclatasvir with ribavirin). The efficacy and safety of the treatments were evaluated. Liver function tests were assessed at baseline, at 4 weeks, at end of treatment (EOT) and at 12-week post-treatment follow-up.

Results: SVR12 was nearly equal in patients who received dual and triple therapy (98.5%). The most common reported AEs were headache and fatigue. There was a significant improvement in liver function parameters at SVR12.

Conclusion: Sofosbuvir plus daclatasvir with or without ribavirin (RBV) were highly effective and well-tolerated.